3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
The Synergy Between Compounding Pharmacy and Functional Medicine for Optimal Health
Schedule your free consultation now to get tailored support and expert advice
Systematic reviews of BPC-157 in musculoskeletal applications identified 36 studies demonstrating improved functional, structural, and biomechanical outcomes across muscle, tendon, ligament, and bone injuries in preclinical models
And then they wonder why their compounds are not working, or worse, why they are experiencing reactions they cannot explain
Storage Guide Overview How Long Can You Store BPC 157